Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine

References

[1] Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ (2020) Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 383:2427–2438

[2] Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, Torres JL, Okba NMA, Claireaux M, Kerster G (2020) Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369:643–650

[3] Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng C (2020) Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput Single-cell sequencing of convalescent patients’ B cells. Cell 182:73–84

[4] Jones I, Roy P (2021) Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 397(10275):642–643

[5] Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S (2020) Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584:115–119

[6] Lerner RA (2006) Manufacturing immunity to disease in a test tube: the magic bullet realized. Angew Chem 45:8106–8125

[7] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615

[8] Rajan S, Kierny MR, Mercer A, Wu J, Tovchigrechko A, Wu H, Dall Acqua WF, Xiao X, Chowdhury PS (2018) Recombinant human B cell repertoires enable screening for rare, specific, and natively paired antibodies. Commun Biol 1:5

[9] von Boehmer L, Liu C, Ackerman S, Gitlin AD, Wang Q, Gazumyan A, Nussenzweig MC (2016) Sequencing and cloning of antigenspecific antibodies from mouse memory B cells. Nat Protoc 11:1908–1923

[10] Wang B, DeKosky BJ, Timm MR, Lee J, Normandin E, Misasi J, Kong R, McDaniel JR, Delidakis G, Leigh KE (2018) Functional interrogation and mining of natively paired human V (H):V(L) antibody repertoires. Nat Biotechnol 36:152–155

[11] Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J (2020) Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182:713–721.e719

[12] Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS (2021) Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv, 2021.2001.2025.428137.

[13] Wen GP, He L, Tang ZM, Wang SL, Zhang X, Chen YZ, Lin X, Liu C, Chen JX, Ying D (2020) Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nat Commun 11:3971

[14] Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, Wang B, Zhao Z, Song X, Chen Y (2020) A single dose of an adenovirusvectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 11:4081

[15] Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 21:39–51

RIGHTS & PERMISSIONS

The Author(s) 2021